The Celtics got lots of bench support Thursday night against the Pistons but Joe Mazzulla singled out one performance.
"After three years together, I would think he’d be ready to take that step if he truly wanted to. I, on the other hand, do ...
Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR solid tumors LEXINGTON, Mass., Dec.